Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

B Cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tongji Hospital of Tongji University, Shanghai, China
Contact: Study coordinator (Wenjun Zhang, Ph.D) · zhangwenjun@tongji.edu.cn · 13918803148

Study leads

Wenjun Zhang, Ph.D.
Principal Investigator
Tongji Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

SynKIR-310 for Relapsed/Refractory B-NHL

B Cell Lymphoma · NHL, Adult · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Atlanta, United States

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Primary Central Nervous System Lymphoma (PCNSL) · Diffuse Large B Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China